Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: J Heart Lung Transplant. 2023 Oct 18;43(3):461–470. doi: 10.1016/j.healun.2023.10.013

Table 3:

Survival and secondary outcomes post DCD HT vs. DBD HT

Unmatched cohort Matched Cohort
DCD
(n=425)
DBD
(n=9977)
P-value DCD
(n=425)
DBD
(n=850)
p-value
Survival % (95% CI) 0.72
HR=0.937 (0.655–1.34)
0.22
HR=1.3 (0.84–2)
 6mo 94 (9196) 92 (92–93) 94 (91–96) 94 (92–96)
 12mo 92 (8995) 90 (90–91) 92 (89–95) 93 (91–95)
 18mo 90 (8594) 88 (87–88) 90 (85–94) 91 (89–93)
 24mo 80 (71–91) 86 (85–86) 80 (71–91) 88 (86–91)
Stroke, n (%) 14 (3.3%) 385 (3.9%) 0.264 14 (3.3%) 26 (3.1%) 0.465
Acute Rejection episodes, n (%) 82 (19%) 1752 (18%) 0.383 82 (19%) 152 (18%) 0.578
Dialysis Requirement, n (%) 73 (17%) 1678 (16.8%) 0.892 73 (17%) 111 (13%) 0.059
Hospital Length of Stay, median [IQR] 16 [12–24] 17 [12–26] 0.097 16 [12–24] 16 [12–24] 0.894
Cause of Death, n (%)
 Cardiac 6 (1.4%) 244 (2.4%) 0.172 6 (1.4%) 21 (2.5%) 0.215
 Pulmonary 3 (0.7%) 74 (0.7%) 0.932 3 (0.7%) 7 (0.8%) 0.822
 Infection 11 (2.6%) 278 (2.8%) 0.807 11 (2.6%) 21 (2.5%) 0.899
 CVA 1 (0.2%) 90 (0.9%) 0.148 1 (0.2%) 3 (0.4%) 0.723
 Other 10 (2.4%) 365 (3.7%) 0.157 10 (2.4%) 22 (2.6%) 0.800